Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT04535999
PHASE4

Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis (Phase IV)

Sponsor: University of Pennsylvania

View on ClinicalTrials.gov

Summary

This study will be an open label study of secukinumab for the treatment of nail psoriasis. Secukinumab is an FDA-approved treatment for psoriasis. We will examine time to response and different methods of defining nail disease response.

Official title: Phase IV Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis

Key Details

Gender

All

Age Range

18 Years - 85 Years

Study Type

INTERVENTIONAL

Enrollment

16

Start Date

2022-02-07

Completion Date

2025-05-30

Last Updated

2026-10-30

Healthy Volunteers

No

Conditions

Interventions

DRUG

Secukinumab Auto-Injector

300 mg- Every 4 weeks after loading dose (Loading Dose-300 mg once weekly for 5 weeks)

Locations (1)

Hospital at the University of Pennsylvania

Philadelphia, Pennsylvania, United States